Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies (Details Narrative)

v3.20.1
Summary of Significant Accounting Policies (Details Narrative) - USD ($)
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2019
Patent and licensing costs $ 133,467 $ 190,773  
Concentration of risk, percentage 10.00% 10.00%  
Deferred setup and organization costs, amortization period 180 months    
Unrecognized tax benefits  
General and Administrative Expense [Member]      
Concentration of risk, percentage 45.60% 48.90%  
Research and Development Expense [Member] | One Vendors and Consultants [Member]      
Concentration of risk, percentage 31.70% 68.20%  
Research and Development Expense [Member] | Two Vendors and Consultants [Member]      
Concentration of risk, percentage 20.80% 20.70%  
Research and Development Expense [Member] | Three Vendors and Consultants [Member]      
Concentration of risk, percentage 14.40%    
Research and Development Expense [Member] | Four Vendors and Consultants [Member]      
Concentration of risk, percentage 12.50%    
Research and Development Expense [Member] | Five Vendors and Consultants [Member]      
Concentration of risk, percentage 11.00%